Clinical Trial Update: Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer [Phase 1]

View source ↗

Summary

This update covers completion of a Phase I/II study of AZD2281 (olaparib) in combination with paclitaxel for metastatic triple-negative breast cancer. The study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• AZD2281 (olaparib)

Snippet

Sponsor: AstraZeneca | Conditions: Breast Cancer, Triple Negative Breast Cancer | Phase 1 | Status: COMPLETED